

To: 5.1.2e @bmbwf.gv.at; 5.1.2e @bmbwf.gv.at; 5.1.2e @ages.at; 5.1.2e @ages.at;
 5.1.2e @gesundheitsministerium.gv.at; 5.1.2e @gesundheitsministerium.gv.at;
 5.1.2e @bmdw.gv.at; 5.1.2e @bmdw.gv.at; 5.1.2e @bmbwf.gv.at; 5.1.2e @bmbwf.gv.at;
 5.1.2e @aihta.at; 5.1.2e @aihta.at; 5.1.2e @sozialministerium.at; 5.1.2e @sozialministerium.at;
 5.1.2e @sciensano.be; 5.1.2e @sciensano.be;
 5.1.2e @spw.wallonie.be; 5.1.2e @spw.wallonie.be; 5.1.2e @gmail.com; 5.1.2e @gmail.com;
 5.1.2e @gmail.com; 5.1.2e @gmail.com; 5.1.2e @ncipd.org; 5.1.2e @ncipd.org;
 5.1.2e @bfm.hr; 5.1.2e @bfm.hr; 5.1.2e @medri.uniri.hr; 5.1.2e @medri.uniri.hr;
 5.1.2e @lf1.cuni.cz; 5.1.2e @lf1.cuni.cz; 5.1.2e @msmt.cz; 5.1.2e @msmt.cz; 5.1.2e @ufm.dk; 5.1.2e @ufm.dk;
 5.1.2e @etag.ee; 5.1.2e @etag.ee; 5.1.2e @businessfinland.fi; 5.1.2e @businessfinland.fi;
 5.1.2e @fimea.fi; 5.1.2e @fimea.fi; 5.1.2e @fimea.fi; 5.1.2e @fimea.fi; 5.1.2e @fimea.fi;
 5.1.2e @thl.fi; 5.1.2e @thl.fi; 5.1.2e @thl.fi; 5.1.2e @thl.fi; 5.1.2e @aka.fi; 5.1.2e @aka.fi;
 5.1.2e @recherche.gouv.fr; 5.1.2e @recherche.gouv.fr; 5.1.2e @recherche.gouv.fr;
 5.1.2e @diplomatie.gouv.fr; 5.1.2e @diplomatie.gouv.fr;
 5.1.2e @recherche.gouv.fr; 5.1.2e @recherche.gouv.fr;
 5.1.2e @finances.gouv.fr; 5.1.2e @finances.gouv.fr;
 5.1.2e @sante.gouv.fr; 5.1.2e @sante.gouv.fr;
 5.1.2e @recherche.gouv.fr; 5.1.2e @recherche.gouv.fr;
 5.1.2e @sante.gouv.fr; 5.1.2e @sante.gouv.fr; 5.1.2e @inserm.fr; 5.1.2e @inserm.fr;
 5.1.2e @sante.gouv.fr; 5.1.2e @sante.gouv.fr; 5.1.2e @dlr.de; 5.1.2e @dlr.de;
 5.1.2e @pei.de; 5.1.2e @pei.de; 5.1.2e @bmbf.bund.de; 5.1.2e @bmbf.bund.de;
 5.1.2e @dlr.de; 5.1.2e @dlr.de; 5.1.2e @certh.gr; 5.1.2e @certh.gr;
 5.1.2e @mnec.gr; 5.1.2e @mnec.gr; 5.1.2e @gsrt.gr; 5.1.2e @gsrt.gr; 5.1.2e @med.uoa.gr; 5.1.2e @med.uoa.gr;
 5.1.2e @hotmail.com; 5.1.2e @hotmail.com; 5.1.2e @ttk.elte.hu; 5.1.2e @ttk.elte.hu;
 5.1.2e @richter.hu; 5.1.2e @richter.hu; 5.1.2e @nkfih.gov.hu; 5.1.2e @nkfih.gov.hu; 5.1.2e @hrb.ie; 5.1.2e @hrb.ie;
 5.1.2e @health.gov.ie; 5.1.2e @health.gov.ie; 5.1.2e @sanita.it; 5.1.2e @sanita.it;
 5.1.2e @hotmail.com; 5.1.2e @hotmail.com; 5.1.2e @unimib.it; 5.1.2e @unimib.it;
 5.1.2e @biomed.lu.lv; 5.1.2e @biomed.lu.lv; 5.1.2e @ismuni.lt; 5.1.2e @ismuni.lt;
 5.1.2e @vvkt.lt; 5.1.2e @vvkt.lt; 5.1.2e @mita.lt; 5.1.2e @mita.lt;
 5.1.2e @mita.lt; 5.1.2e @mita.lt; 5.1.2e @mesr.etat.lu; 5.1.2e @mesr.etat.lu;
 5.1.2e @pt.lu; 5.1.2e @pt.lu; 5.1.2e @gov.mt; 5.1.2e @gov.mt; 5.1.2e @gov.mt; 5.1.2e @gov.mt; 5.1.2e @gov.mt;
 5.1.2e @gov.mt; 5.1.2e @gov.mt; 5.1.2e @mdb.org.mt; 5.1.2e @mdb.org.mt; 5.1.2e @maltaenterprise.com;
 5.1.2e @gov.mt; 5.1.2e @gov.mt; 5.1.2e @maltaenterprise.com;
 5.1.2e @minvws.nl; 5.1.2e @minvws.nl; 5.1.2e @minocw.nl; 5.1.2e @minocw.nl; 5.1.2e @minocw.nl;
 5.1.2e @minezk.nl; 5.1.2e @minezk.nl; 5.1.2e @rvo.nl; 5.1.2e @rvo.nl; 5.1.2e @rvo.nl; 5.1.2e @rvm.nl;
 5.1.2e @minvws.nl; 5.1.2e @minvws.nl; 5.1.2e @minvws.nl; 5.1.2e @minvws.nl;
 5.1.2e @minvws.nl; 5.1.2e @minvws.nl; 5.1.2e @minvws.nl; 5.1.2e @minvws.nl;
 5.1.2e @minbuza.nl; 5.1.2e @minbuza.nl; 5.1.2e @forskingsradet.no; 5.1.2e @forskingsradet.no; 5.1.2e @fhi.no; 5.1.2e @fhi.no;
 5.1.2e @fhi.no; 5.1.2e @ncbr.gov.pl; 5.1.2e @ncbr.gov.pl;
 5.1.2e @abm.gov.pl; 5.1.2e @abm.gov.pl; 5.1.2e @abm.gov.pl; 5.1.2e @abm.gov.pl;
 5.1.2e @abm.gov.pl; 5.1.2e @abm.gov.pl; 5.1.2e @aicib.pt; 5.1.2e @aicib.pt;
 5.1.2e @ibet.pt; 5.1.2e @ibet.pt; 5.1.2e @gmail.com; 5.1.2e @gmail.com; 5.1.2e @med.uminho.pt; 5.1.2e @med.uminho.pt;
 5.1.2e @research.gov.ro; 5.1.2e @research.gov.ro; 5.1.2e @insp.gov.ro; 5.1.2e @insp.gov.ro;
 5.1.2e @umfiasi.ro; 5.1.2e @umfiasi.ro; 5.1.2e @yahoo.com; 5.1.2e @yahoo.com;
 5.1.2e @umfcd.ro; 5.1.2e @umfcd.ro; 5.1.2e @yahoo.com; 5.1.2e @yahoo.com;
 5.1.2e @yahoo.com; 5.1.2e @yahoo.com; 5.1.2e @research.gov.ro; 5.1.2e @research.gov.ro;
 5.1.2e @health.gov.sk; 5.1.2e @health.gov.sk; 5.1.2e @biohub.sk; 5.1.2e @biohub.sk;
 5.1.2e @savba.sk; 5.1.2e @savba.sk; 5.1.2e @savba.sk; 5.1.2e @savba.sk;
 5.1.2e @minedu.sk; 5.1.2e @minedu.sk; 5.1.2e @cvtisr.sk; 5.1.2e @cvtisr.sk;
 5.1.2e @gov.si; 5.1.2e @gov.si; 5.1.2e @jazmp.si; 5.1.2e @jazmp.si;
 5.1.2e @jazmp.si; 5.1.2e @jazmp.si; 5.1.2e @jazmp.si; 5.1.2e @jazmp.si;
 5.1.2e @jazmp.si; 5.1.2e @jazmp.si; 5.1.2e @nlzoh.si; 5.1.2e @nlzoh.si;
 5.1.2e @nijz.si; 5.1.2e @nijz.si; 5.1.2e @nijz.si; 5.1.2e @nijz.si; 5.1.2e @isciii.es; 5.1.2e @isciii.es;
 5.1.2e @cdti.es; 5.1.2e @cdti.es; 5.1.2e @aemps.es; 5.1.2e @aemps.es; 5.1.2e @vr.se; 5.1.2e @vr.se;
 5.1.2e @vr.se; 5.1.2e @vr.se; 5.1.2e @vr.se; 5.1.2e @vr.se; 5.1.2e @lakemedelsverket.se; 5.1.2e @lakemedelsverket.se;
 5.1.2e @lakemedelsverket.se; 5.1.2e @vinnova.se; 5.1.2e @vinnova.se;
 5.1.2e @icm.uu.se; 5.1.2e @icm.uu.se; 5.1.2e @sbfi.admin.ch; 5.1.2e @sbfi.admin.ch;
 5.1.2e @sbfi.admin.ch; 5.1.2e @sbfi.admin.ch;
 5.1.2e @sbfi.admin.ch; 5.1.2e @sbfi.admin.ch;
 5.1.2e @consilium.europa.eu; 5.1.2e @consilium.europa.eu;
 5.1.2e @consilium.europa.eu; 5.1.2e @consilium.europa.eu; 5.1.2e @lshmt.ac.uk; 5.1.2e @lshmt.ac.uk;
 5.1.2e @eib.org; 5.1.2e @eib.org; 5.1.2e @eib.org; 5.1.2e @eib.org; 5.1.2e @minocw.nl; 5.1.2e @minocw.nl;
 5.1.2e @immunogenes.com; 5.1.2e @immunogenes.com; 5.1.2e @martinalutter.com; 5.1.2e @martinalutter.com;
 5.1.2e @ecrin.org; 5.1.2e @ecrin.org; 5.1.2e @hrb.ie; 5.1.2e @hrb.ie; 5.1.2e @reper.maec.es; 5.1.2e @reper.maec.es;
 5.1.2e @reper.maec.es; 5.1.2e @gesundheitsministerium.gv.at; 5.1.2e @gesundheitsministerium.gv.at;


[illegible]

<u>ON BEHALF OF</u>	5.1.2e
----------------------------	--------

Dear all,

Please find hereunder a flash report following the “ERAvsCorona Ad hoc group” meeting which was held on 6 July 2020.

Kind regards,



European Commission
DG Research & Innovation
RTD.E - People
1049 Brussels/Belgium

5.1.2e
5.1.2e @ec.europa.eu
<http://ec.europa.eu/research>

EU research & innovation delivering for you!

The objectives of the meeting were to provide an overview of the outcomes of the various subgroups, and agree

about the next steps, as regards the four sub-groups and the Ad hoc group. It was also an opportunity to share information on relevant EU COVID-19 activities, mostly on the R&I side.

The Ad hoc group was provided with information regarding the EU Strategy for COVID-19 vaccines, as well as an update regarding the actions developed under the ERAvsCorona Action Plan.

Each subgroup (testing, clinical trials, manufacturing, financing) then presented their objectives, work performed and outcome. The outcomes of the subgroups were found of high value, and members thanked for their work. In addition to documents emanating from subgroups already circulated, information about manufacturing capacity emanating from the work of the 'manufacturing' subgroup was deemed important to circulate.

When it comes to the continuation of the subgroups, there was general agreement that these groups have delivered as much as could be under this configuration. It was proposed that any potential further work in the area of the subgroups should be undertaken using the usual channels for decision-making at EU level, i.e. using regular comitology (Programme Committee), expert groups (such as SANTE's Steering Group on Health Promotion, Disease Prevention and Management of Non-Communicable Diseases (SGPP) or other expert groups in DG SANTE) or relevant Council groups. SK underlined their wish to continue work under the 'manufacturing' subgroup, although it was not clear whether they could agree to continue work under the regular channels. FR will provide their position on subgroups asap.

The participants of the Ad hoc group were also consulted regarding a potential wrapping up the work also of the Ad hoc group, although it was made clear that the decision to do so would be for the group of R&I Directors-General, who will be meeting on Wednesday 8 July. Opinions were split between MS/AC delegations favourable to wrapping up the Ad hoc group (e.g. DK, PT, CH) and those in favour of an additional Ad hoc group meeting in September to examine work done over the summer and assess how remaining work could be taken over through formal channels (e.g. SE, AT). Both options will then be tabled at the meeting of R&I Directors-General of 8 July, for decision-making.

MS/AC overall conveyed their high appreciation of the work by the European Commission in setting up and managing the Ad hoc group and the subgroups, which were seen as a good way to informally exchange important information and helping the coordination of R&I and health activities also at national level.